# Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

> **NCT02043548** · PHASE2 · COMPLETED · sponsor: **Chester Oddis** · enrollment: 36 (actual)

## Conditions studied

- Dermatomyositis
- Polymyositis

## Interventions

- **DRUG:** tocilizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02043548
- **Lead sponsor:** Chester Oddis
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-07-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02043548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02043548, "Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02043548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*